MINI REVIEW article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1613849
Non-Hematopoietic Roles of Erythropoietin in Inflammation and Metabolic Disorders
Provisionally accepted
Satoru Sugimoto*
Takeshi Goda- Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyōto, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Erythropoietin (EPO), a glycoprotein hormone primarily produced by the kidneys, is essential for erythropoiesis. Beyond its well-established hematopoietic function, EPO has emerged as a regulator of metabolic inflammation. Obesity-induced chronic inflammation underlies insulin resistance, a key driver of metabolic disorders such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH). Recent evidence shows EPO exerts anti-inflammatory effects in insulin-sensitive tissues, thereby improving insulin sensitivity in the context of obesity. Although EPO is clinically approved for treating anemia in both neonates and adults, further evaluation is needed to establish its safety and tolerability when repurposed for metabolic indications across these populations. Nevertheless, to overcome the hematopoietic side effects of native EPO, researchers have developed non-hematopoietic analogs with selective tissue-protective actions. These analogs are currently under investigation and have shown therapeutic potential without erythropoietic side effects. This review summarizes the anti-inflammatory roles of EPO in obesity-related metabolic dysfunction, particularly in white adipose tissue (WAT) and the liver, and discusses the therapeutic potential of non-hematopoietic EPO analogs.
Keywords: Erythropoietin, Obesity, Inflammation, Liver, white adipose tissue, nonhematopoietic EPO analogs
Received: 17 Apr 2025; Accepted: 26 Jun 2025.
Copyright: © 2025 Sugimoto and Goda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Satoru Sugimoto, Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyōto, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.